FDA Pushes Review Date for Ocrelizumab in MS FDA Pushes Review Date for Ocrelizumab in MS

Although the FDA ' s decision on the hotly anticipated drug was expected to come next week, the agency has decided to extend the process until the spring, the manufacturer says.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news